Jun 07, 2021 4:05pm EDT Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
May 20, 2021 4:05pm EDT Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
May 13, 2021 4:55pm EDT Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
May 07, 2021 8:30am EDT Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
Mar 25, 2021 4:06pm EDT Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
Mar 22, 2021 9:15am EDT Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
Mar 17, 2021 9:15am EDT Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
